What is vertebrogenic pain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is Vertebrogenic Pain?

Vertebrogenic pain is a specific subtype of chronic low back pain that originates from structural damage and inflammatory changes in the vertebral endplates, with pain signals transmitted through the basivertebral nerve (BVN) located within the vertebral body 1, 2.

Pathophysiology

The mechanism involves a cascade of pathological changes:

  • Endplate damage leads to chronic inflammation that triggers proliferation of nociceptors (pain receptors) in the vertebral endplates
  • These sensitized nociceptors transmit pain signals via the basivertebral nerve, which runs posteriorly through the vertebral body
  • Chemical sensitization and mechanical stimulation of these nerves result in the perception of chronic low back pain 2, 3

Imaging Biomarkers

Modic changes on MRI serve as the primary diagnostic imaging marker for vertebrogenic pain:

  • Type 1 Modic changes: Indicate active inflammation and edema in the bone marrow adjacent to endplates
  • Type 2 Modic changes: Represent fatty infiltration of the bone marrow
  • Both types are associated with nociceptive signaling from the basivertebral nerve 1, 2

These changes can present as mixed types or interconvert over time, reflecting the dynamic nature of endplate pathology 1.

Clinical Context

Vertebrogenic pain represents one distinct phenotype within the broader spectrum of chronic low back pain. It differs from:

  • Annulogenic pain (arising from annular disc fissures)
  • Facet-mediated pain (from facet joints)
  • Myofascial pain (from soft tissue dysfunction)

The identification of vertebrogenic pain as a specific entity is relatively recent, emerging from advances in understanding the innervation patterns of vertebral bodies and the role of endplate pathology 4.

Treatment Implications

Recognition of vertebrogenic pain has led to targeted interventions, particularly basivertebral nerve ablation (BVNA), which uses radiofrequency energy to interrupt pain transmission from pathological endplates 2, 3, 5. This represents a mechanism-specific approach rather than empirical treatment.

Diagnostic Challenges

A major limitation is the lack of standardized diagnostic criteria, which creates inconsistency in research outcomes and clinical application 1. Patient selection currently relies on the combination of:

  • Clinical suspicion of anterior element spinal pain
  • Presence of Type 1 or Type 2 Modic changes on MRI 5

References

3
Research

Basivertebral Nerve Ablation: Part 2.

AJNR. American journal of neuroradiology, 2026

Related Questions

What symptoms and clinical features indicate candidacy for basivertebral nerve ablation (BVNA) in a patient with persistent axial low‑back pain after an osteoporotic vertebral compression fracture?
What are Modic Type II (Grade 2) changes and what is the recommended management?
What is the recommended management for Modic type 1 degenerative endplate changes causing low back pain?
What is the recommended management for Modic type 1 and type 2 changes on lumbar MRI?
With MRI showing significant edema at L2‑L3 consistent with Modic type 1 change and discitis/osteomyelitis unlikely, should the patient be referred urgently to neurosurgery and what management steps are indicated?
In cystic fibrosis, is the sweat sodium concentration greater than the sweat chloride concentration?
In a patient with a seizure but normal brain magnetic resonance imaging (MRI) and electroencephalogram (EEG), should antiepileptic drug (AED) therapy be continued, and how should the underlying cause be investigated?
In a patient with fever, dry cough, night chills, throat irritation, and a mild productive cough on day 3 despite three days of azithromycin, levocetirizine, and paracetamol 650 mg, what is the next appropriate management?
What immunoreactive trypsinogen concentration on a newborn screening test is considered abnormal and what follow‑up actions are recommended?
What is the appropriate next step for a patient with persistent, worsening fever on day 3 despite three days of azithromycin, levocetirizine 5 mg daily, and paracetamol 650 mg as needed?
Is fecal elastase low in cystic fibrosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.